Prostate cancer: primary ADT monotherapy not suitable for localized disease

Nat Rev Urol. 2014 Jun;11(6):309-10. doi: 10.1038/nrurol.2014.119. Epub 2014 May 27.

Abstract

Although current guidelines do not endorse the use of primary androgen deprivation therapy (PADT) as monotherapy for localized prostate cancer, many patients continue to receive this treatment. New outcomes research confirms that there is no clear reason for use of PADT in men with localized prostate cancer.

MeSH terms

  • Androgen Antagonists / adverse effects
  • Androgen Antagonists / therapeutic use*
  • Biomarkers, Tumor / blood*
  • Evidence-Based Medicine
  • Guidelines as Topic
  • Humans
  • Male
  • Neoplasm Grading
  • Neoplasm Staging
  • Prostate-Specific Antigen / blood*
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / pathology*
  • Randomized Controlled Trials as Topic
  • Survival Analysis
  • Treatment Outcome

Substances

  • Androgen Antagonists
  • Biomarkers, Tumor
  • Prostate-Specific Antigen